Cobicistat

Major

Cobicistat Felodipine Plendil® Increased calcium channel blocker exposure and an increased risk of calcium channel blocker-related adverse effects Details Cobicistat Fentanyl Transdermal Patch Duragesic® Increased fentaNYL exposure and an increased risk of prolonged opioid effects Details Cobicistat Fluvastatin Lescol Increased HMG-CoA reductase inhibitor that also are OATP1B1/B3 substrates exposure Details Cobicistat Futibatinib Lytgobi Increased futibatinib exposure and increased risk of futibatinib-related adverse reactions Details Cobicistat Gilteritinib Xospata Increased gilteritinib plasma concentrations Details Cobicistat Glasdegib Daurismo Increased glasdegib exposure Details Cobicistat Hydrocortisone Ala-Cort Increased hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details Cobicistat Hydrocortisone Injection A-Hydrocort® Increased hydrocortisone exposure and an increased risk of hydrocortisone-related adverse reactions Details Cobicistat Ibrexafungerp Brexafemme Increased ibrexafungerp exposure Details Cobicistat Ibrutinib Imbruvica Increased ibrutinib exposure Details Cobicistat Ifosfamide Injection Ifex Decreased ifosfamide effectiveness Details Cobicistat Infigratinib Truseltiq Increased infigratinib plasma concentrations Details Cobicistat Istradefylline Nourianz Increased istradefylline exposure Details Cobicistat Ixabepilone Injection IXEMPRA Increased ixabepilone exposure and increase in the incidence and severity of adverse reactions Details Cobicistat Ketoconazole Topical Extina® Foam Increased cobicistat exposure and an increased ketoconazole exposure Details Cobicistat Lefamulin Xenleta Increased lefamulin exposure and an increased risk of lefamulin-related adverse reactions Details Cobicistat Lenacapavir Injection Sunlenca Increased lenacapavir exposure Details Cobicistat Lenacapavir Oral Sunlenca Increased lenacapavir exposure Details Cobicistat Leniolisib Joenja Increased leniolisib exposure Details Cobicistat Letermovir Injection Prevymis Increased CYP3A substrate exposure Details Cobicistat Loperamide Diamode An increased loperamide exposure and an increased risk of loperamide-related adverse reactions Details Cobicistat Lumateperone Caplyta Increased lumateperone exposure, an increased risk of lumateperone-related adverse reactions, an increased cobicistat exposure and... Details Cobicistat Lurbinectedin Injection Zepzelca Increased lurbinectedin exposure and an increased risk of lurbinectedin-related adverse reactions Details Cobicistat Macitentan Opsumit Increased macitentan exposure Details Cobicistat Maraviroc Selzentry Increased maraviroc exposure Details Cobicistat Midostaurin Rydapt Increased midostaurin exposure Details Cobicistat Mirvetuximab Soravtansine-Gynx Injection Elahere Increased unconjugated DM4 exposure and an increased risk of mirvetuximab soravtansine-gynx adverse reactions Details Cobicistat Mitapivat Aqvesme Increased mitapivat exposure and an increased risk of mitapivat-related adverse reactions Details Cobicistat Mometasone Asmanex Increased mometasone exposure and an increased risk for systemic corticosteroid effects Details Cobicistat Mometasone Nasal Spray Nasonex Increased mometasone exposure and an increased risk for systemic corticosteroid effects Details Cobicistat Mometasone Oral Inhalation Asmanex Increased mometasone exposure and an increased risk for systemic corticosteroid effects Details Cobicistat Mometasone Topical Elocon® Increased mometasone exposure and an increased risk for systemic corticosteroid effects Details Cobicistat Morphine Injection Astramorph® PF Increased morphine exposure and an increased risk of morphine-related adverse effects (hypotension, respiratory depression, profou... Details Cobicistat Nebivolol Bystolic Increased beta blocker exposure and an increased risk of beta blocker-related adverse effects Details Cobicistat Neratinib Nerlynx Increased neratinib exposure and risk of toxicity Details Cobicistat Nifedipine Adalat® Increased NIFEdipine exposure and an increased risk of hypotension, bradycardia, or acute renal injury Details Cobicistat Nimodipine Nimotop Increased risk of significant hypotension Details Cobicistat Nisoldipine Sular Increased nisoldipine exposure Details Cobicistat Olaparib Lynparza Increased olaparib exposure Details Cobicistat Orlistat Alli Reduced efficacy of antiretrovirals, loss of virological control Details